OTCMKTS:CVSI CV Sciences (CVSI) Stock Price, News & Analysis → Your Portfolio’s Shield Against Inflation: Gold’s Surge and AI Breakthroughs (From InvestorPlace) (Ad) Free CVSI Stock Alerts $0.05 +0.00 (+1.21%) (As of 05/10/2024 08:56 PM ET) Add Compare Share Share Today's Range$0.05▼$0.0650-Day Range$0.03▼$0.0552-Week Range$0.03▼$0.06Volume281,800 shsAverage Volume248,815 shsMarket Capitalization$8.16 millionP/E Ratio2.50Dividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort Interest Get CV Sciences alerts: Email Address Ad InvestorPlaceYour Portfolio’s Shield Against Inflation: Gold’s Surge and AI BreakthroughsWhile gold may be thanking China for its recent growth, this sector is currently thanking Elon Musk. As crazy as it sounds, artificial intelligence just got one step closer to ushering in "the next step in human evolution"... and minting new millionaires. And it's all thanks to Musk's latest AI creation.Click to watch this device in action About CV Sciences Stock (OTCMKTS:CVSI)CV Sciences, Inc. develops, manufactures, markets, and sells herbal supplements and hemp-based cannabidiol (CBD) in North America. It operates in two segments, Consumer Products and Specialty Pharmaceutical. The company offers its products under the PlusCBD, ProCBD, HappyLane, CVAcute, CVDefense, and PlusCBD Pet brands in the health care market sector, including nutraceutical, beauty care, specialty foods, and pet products through its websites, elect distributors, brick and mortar retailers, and select e-tailers. It is also developing cannabinoids intended to treat medical indications, including CVSI-007 that combines CBD and nicotine for the treatment of smokeless tobacco use and addiction. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California.Read More CVSI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CVSI Stock News HeadlinesMay 8, 2024 | prnewswire.comCV Sciences, Inc. To Announce First Quarter 2024 Results On May 14, 2024April 1, 2024 | finance.yahoo.comCV Sciences, Inc. (PNK:CVSI) Q4 2023 Earnings Call TranscriptMay 13, 2024 | InvestorPlace (Ad)Elon Musk’s Next Move Will Disrupt AI ForeverA revolutionary venture that is set to get rolled out by May 16. One well-connected Silicon Valley VC has uncovered a way for anybody to claim a stake in "Elon Musk's AI 2.0" with as little as $100.March 28, 2024 | investorplace.comCVSI Stock Earnings: CV Sciences Reported Results for Q4 2023March 28, 2024 | prnewswire.comCV Sciences, Inc. Reports Fiscal Year-End 2023 Financial ResultsMarch 27, 2024 | wsj.comCV Sciences Inc.March 26, 2024 | finance.yahoo.comCV Sciences, Inc. Expands +PlusCBD Pet Product Offerings with the Launch of Pet ChewsMarch 21, 2024 | prnewswire.comCV SCIENCES, INC. TO ANNOUNCE YEAR END AND FOURTH QUARTER 2023 RESULTS ON MARCH 28, 2024May 13, 2024 | InvestorPlace (Ad)Elon Musk’s Next Move Will Disrupt AI ForeverA revolutionary venture that is set to get rolled out by May 16. One well-connected Silicon Valley VC has uncovered a way for anybody to claim a stake in "Elon Musk's AI 2.0" with as little as $100.February 22, 2024 | benzinga.comCV Sciences Stock (OTC:CVSI), Short Interest ReportDecember 12, 2023 | finance.yahoo.comCV Sciences, Inc. Acquires Cultured Foods To Enter Plant-Based Food Market, Opening Door For European DistributionNovember 15, 2023 | nz.finance.yahoo.comThe Best Shampoo for Thinning Hair We Tested Is 30% Off Right NowNovember 15, 2023 | finance.yahoo.comCV Sciences, Inc. (PNK:CVSI) Q3 2023 Earnings Call TranscriptNovember 14, 2023 | benzinga.comHemp-Focused Wellness Company: Revenue Jumps To $4.1M, Gross Margin Peaks At 45.1%November 14, 2023 | msn.comCV Sciences GAAP EPS of $0.00, revenue of $4.09MNovember 14, 2023 | finance.yahoo.comCV Sciences, Inc. Reports Third Quarter 2023 Financial ResultsNovember 12, 2023 | morningstar.comCV Sciences Inc CVSINovember 9, 2023 | finance.yahoo.comCV SCIENCES, INC. TO ANNOUNCE THIRD QUARTER 2023 RESULTS ON NOVEMBER 14, 2023September 5, 2023 | finance.yahoo.comCV Sciences, Inc. Launches Reserve Sleep GummiesAugust 15, 2023 | finance.yahoo.comCV Sciences, Inc. (PNK:CVSI) Q2 2023 Earnings Call TranscriptAugust 14, 2023 | seekingalpha.comCV Sciences GAAP EPS of -$0.01, revenue of $4MAugust 14, 2023 | benzinga.comPublicly Traded Hemp-Focused Wellness Company Reports Q2 Results, Here Is What You Need To KnowAugust 14, 2023 | finance.yahoo.comCV Sciences, Inc. Reports Second Quarter 2023 Financial ResultsAugust 1, 2023 | finance.yahoo.comCV SCIENCES, INC. TO ANNOUNCE SECOND QUARTER 2023 RESULTS ON AUGUST 14, 2023July 8, 2023 | finance.yahoo.comCVSI - CV Sciences, Inc.June 1, 2023 | finance.yahoo.comCV Sciences to Participate in LD Micro Invitational ConferenceMay 15, 2023 | msn.comCV Sciences Inc Q1 Revenue Stagnates YoY, Here Is What You Need To KnowSee More Headlines Receive CVSI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CV Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/28/2024Today5/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:CVSI Previous SymbolNASDAQ:CVSI CUSIPN/A CIK1510964 Webwww.cvsciences.com Phone(866) 290-2157Fax619-876-4321Employees42Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)$0.02 Trailing P/E Ratio2.50 Forward P/E RatioN/A P/E GrowthN/ANet Income$3.10 million Net Margins19.38% Pretax Margin19.34% Return on Equity80.98% Return on Assets30.87% Debt Debt-to-Equity RatioN/A Current Ratio1.30 Quick Ratio0.37 Sales & Book Value Annual Sales$16 million Price / Sales0.51 Cash Flow$0.02 per share Price / Cash Flow2.37 Book Value$0.02 per share Price / Book2.50Miscellaneous Outstanding Shares163,230,000Free Float161,106,000Market Cap$8.16 million OptionableNot Optionable Beta0.55 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Joseph D. Dowling (Age 67)CEO, Secretary & Director Comp: $313.07kMr. Joerg Grasser (Age 49)Chief Financial Officer Comp: $228kMr. Tim HitchmanVice President of OperationsMr. Jesse KaragianesSenior Vice President of Revenue GrowthMs. Alyssa DunnOperations ManagerKey CompetitorsBiofronteraNASDAQ:BFRINuCanaNASDAQ:NCNATrevenaNASDAQ:TRVNCadrenal TherapeuticsNASDAQ:CVKDVirios TherapeuticsNASDAQ:VIRIView All Competitors CVSI Stock Analysis - Frequently Asked Questions How have CVSI shares performed in 2024? CV Sciences' stock was trading at $0.0354 on January 1st, 2024. Since then, CVSI shares have increased by 41.2% and is now trading at $0.05. View the best growth stocks for 2024 here. Are investors shorting CV Sciences? CV Sciences saw a decrease in short interest in the month of April. As of April 30th, there was short interest totaling 6,400 shares, a decrease of 90.5% from the April 15th total of 67,700 shares. Based on an average daily trading volume, of 544,900 shares, the days-to-cover ratio is presently 0.0 days. View CV Sciences' Short Interest. How were CV Sciences' earnings last quarter? CV Sciences, Inc. (OTCMKTS:CVSI) posted its earnings results on Thursday, March, 28th. The company reported ($0.01) earnings per share for the quarter. The business earned $3.80 million during the quarter. CV Sciences had a trailing twelve-month return on equity of 80.98% and a net margin of 19.38%. What other stocks do shareholders of CV Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other CV Sciences investors own include Cronos Group (CRON), Charlotte's Web (CWBHF), KushCo (KSHB), Organigram (OGI), GW Pharmaceuticals (GWPH), Tilray (TLRY) and Medical Marijuana (MJNA). How do I buy shares of CV Sciences? Shares of CVSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:CVSI) was last updated on 5/13/2024 by MarketBeat.com Staff From Our PartnersDoes this make you sick?Allegiance GoldExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersThis 1 Biotech Stock has been shocking the marketsHuge AlertsThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorNext President (Not Trump. Not Biden.)The Freeport SocietyThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldHe Is Giving Away BitcoinCrypto Swap ProfitsHow Biden has already won 2024Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CV Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
